|1.||Ogbourne, Steven M: 8 articles (05/2010 - 04/2004)|
|2.||Lord, Janet M: 7 articles (07/2010 - 08/2005)|
|3.||Hampson, Peter: 7 articles (07/2010 - 08/2005)|
|4.||Suhrbier, Andreas: 4 articles (05/2009 - 04/2004)|
|5.||Katsamas, Janelle: 3 articles (05/2010 - 02/2009)|
|6.||Le, Thuy T T: 3 articles (05/2009 - 04/2004)|
|7.||Parsons, Peter G: 3 articles (12/2006 - 04/2004)|
|8.||Welburn, Peter: 2 articles (05/2010 - 02/2009)|
|9.||Siller, Greg: 2 articles (05/2010 - 02/2009)|
|10.||Ersvaer, Elisabeth: 2 articles (01/2010 - 06/2007)|
12/01/2006 - "In this study, we provide evidence that neutrophils are required to prevent relapse of skin tumors following topical treatment with a new anticancer agent, ingenol-3-angelate (PEP005). "
08/01/2008 - "Thus, we describe a novel route by which the anti-tumor agent PEP005 regulates the recruitment of cytotoxic leukocytes by directly activating EC in a PKC-delta dependent manner."
08/01/2008 - "Crucially, the cytotoxic functions of neutrophils recruited to the tumor in response to topical application of PEP005 are necessary for effective ablation of the treated lesion. "
08/01/2008 - "The modes of action of the novel anti-skin tumor agent ingenol-3-angelate (PEP005) are incompletely understood. "
08/01/2008 - "The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner."
07/01/2015 - "We report that ingenol-3-angelate (PEP005), the only active component in a previously FDA approved drug (PICATO) for the topical treatment of precancerous actinic keratosis, can effectively reactivate latent HIV in vitro and ex vivo with relatively low cellular toxicity. "
02/01/2009 - "PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study."
12/01/2011 - "A new compound, PEP005, (ingenol mebutate) should soon enlarge therapeutical options for actinic keratosis. "
06/01/2009 - "Assess the efficacy and safety of ingenol mebutate (formerly PEP005) gel at 3 dosing regimens for the treatment of actinic keratosis. "
|3.||Melanoma (Melanoma, Malignant)
12/01/2004 - "These results indicate that PEP005 may enhance or inhibit sensitivity of melanoma to treatments associated with TRAIL-induced apoptosis depending on the PKC isoform content of melanoma cells."
12/01/2004 - "The results showed that at relatively high concentrations (100 microg/mL), PEP005 killed melanoma cells mainly by induction of necrosis. "
10/15/2006 - "We now describe the in vitro cytostatic effects of PEP005 and the diterpene ester phorbol 12-myristate 13-acetate, observed in 20% of human melanoma cell lines. "
10/15/2006 - "The diterpene ester PEP005 is a novel anticancer agent that activates protein kinase C (PKC) and induces cell death in melanoma at high doses. "
12/01/2004 - "Ingenol 3-angelate (PEP005), one of the active ingredients in an extract from Euphorbia peplus, was shown in preclinical studies to have activity against human melanoma xenografts in nude mice. "
01/01/2013 - "The present study aimed to evaluate the therapeutic potential of two PKCδ activators, N-Benzyladriamycin-14-valerate (AD 198) and ingenol-3-angelate (PEP005), on NHL and MM. In vitro anti-tumor activities of AD 198 and PEP005 were determined using TRAF3-/- mouse B lymphoma and human patient-derived MM cell lines as model systems. "
|5.||Basal Cell Carcinoma (Rodent Ulcer)
|2.||Protein Isoforms (Isoforms)
|4.||TNF Receptor-Associated Factor 3
|5.||N-benzyladriamycin-14-valerate (AD 198)
|6.||Protein Kinase C
|8.||Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)
|10.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Traditional Medicine (Folk Remedies)
|4.||Drug Therapy (Chemotherapy)